Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24799782 | 1.00 | CTSK (0.48) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL21098345 | 0.94 | ACE (0.48) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL17489335 | 0.94 | CTSK (0.54) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL17486773 | 0.91 | CTSK (0.49) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL22433675 | 0.83 | CTSK (0.67) | CTSKPPARACTSSSYK | |
| SCHEMBL693646 | 0.83 | PPARA (0.55) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL3906191 | 0.83 | PPARA (0.55) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL953788 | 0.83 | PPARA (0.55) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL2869086 | 0.83 | PPARA (0.55) | CTSKPPARAKLK7KLK5CTSS | |
| SCHEMBL2869084 | 0.83 | PPARA (0.55) | CTSKPPARAKLK7KLK5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180438-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | Cancer Targeted Technology LLC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230144322-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECHNOLOGY, LLC | 2023-05-11 | — | — | US | disclosed |
| EP-3560937-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | Cancer Targeted Technology LLC (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2970345-B1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECH LLC (US) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144322-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | FOLH1, PSMA2, PSMA6 | CTSK 974/4885PPARA 1116/4885KLK7 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.